Search

KR-102963500-B1 - COMPOSITION FOR PREVENTING AND TREATING PSORIASIS COMPRISING EXTRACTS OF FICUS CARICA

KR102963500B1KR 102963500 B1KR102963500 B1KR 102963500B1KR-102963500-B1

Abstract

The present invention relates to a composition for the prevention, improvement, or treatment of psoriasis comprising a fig fruit extract as an active ingredient. The fig fruit extract according to the present invention inhibits the production of NO and reduces the expression of inflammatory proteins, inhibits the phosphorylation of JAK1 and STAT3, which are proteins of the JAK-STAT signaling pathway, and inhibits the release of β-hexozaminidase, thereby effectively preventing, improving, or treating psoriasis.

Inventors

  • 이미영
  • 이정화

Assignees

  • 순천향대학교 산학협력단

Dates

Publication Date
20260511
Application Date
20220902

Claims (8)

  1. A pharmaceutical composition for the prevention or treatment of psoriasis, comprising fig ( Ficus carica ) fruit extract as an active ingredient.
  2. A composition according to claim 1, wherein the extract is extracted with alcohol.
  3. A composition according to claim 1, wherein the extract inhibits the production of NO and reduces the expression of inflammatory proteins.
  4. A composition according to claim 1, wherein the extract inhibits the phosphorylation of JAK1 and STAT3, which are proteins of the JAK-STAT signaling pathway, and inhibits the release of β-hexozaminidase.
  5. A topical skin composition for the prevention or treatment of psoriasis, comprising fig ( Ficus carica ) fruit extract as an active ingredient.
  6. A cosmetic composition for the prevention or improvement of psoriasis, comprising fig ( Ficus carica ) fruit extract as an active ingredient.
  7. delete
  8. A method for the prevention or treatment of psoriasis comprising applying a pharmaceutical composition according to any one of claims 1 to 4 to the skin of an individual other than a human.

Description

Composition for the prevention and treatment of psoriasis comprising fig extracts The present invention relates to a composition for the prevention, improvement, or treatment of psoriasis comprising fig fruit extract as an active ingredient. Psoriasis is an immune-mediated autoimmune skin disease induced by the chronic activation of inflammatory cell infiltration in the skin and dysregulation of epidermal keratinocytes. When psoriasis first develops, small, red, millet-sized rashes appear on the skin, which are covered by white keratinocytes. As these rashes gradually enlarge, they can grow to the size of a coin, or in severe cases, expand to the size of a palm. To date, the pathogenesis of psoriasis has not been fully elucidated and is reported to be associated with a complex mechanism involving the interaction between inflammatory cytokines and the infiltration of immune cells, such as T cells. Common treatment methods for psoriasis include topical therapy, systemic therapy, and phototherapy; recently, immunobiological agents based on the etiology of psoriasis have been developed. Additionally, combination therapies that appropriately combine these agents are widely used to maximize efficacy and minimize side effects. Among these, topical treatments applied directly to the skin in the form of ointments, lotions, or gels are essential medications for psoriasis patients and are the first and most frequently used for symptom control. In particular, when topical treatments are utilized effectively, mild cases of psoriasis often respond well on their own without the need for other treatments. Especially when psoriasis patients have systemic diseases such as digestive disorders or liver or kidney dysfunction, using topical therapy instead of systemic therapy is safer and more effective. Topical treatments include therapies involving steroids, coal tar, anthralin, vitamin D3 and its analogs, and retinoids; however, disadvantages include side effects such as skin thinning, stretch marks, burns, irritation, and photosensitivity. Furthermore, steroids can induce resistance, which affects subsequent steroid treatment. Meanwhile, phototherapy, which involves the administration of psoralen along with ultraviolet B or ultraviolet A, has the disadvantage of accelerating skin aging and increasing the incidence of skin cancer. Therefore, there is a need to develop new psoriasis treatments that are highly effective with minimal side effects. Figure 1 shows the cell viability of fig (Ficus carica) leaf (A) and fruit extracts (B) in Raw 264.7 cells. *P<0.05, ***P<0.001. Figure 2 shows the effect of fig fruit extract on nitric oxide production in Raw 264.7 cells. Fig fruit extract significantly inhibits NO production in LPS-stimulated Raw 264.7 cells in a dose-dependent manner. All data are expressed as mean ± SD ***P<0.001 compared to the control group and ###P<0.001 compared to the LPS group. Figure 3 shows the effect of fig fruit extract on iNOS and COX-2 expression in Raw 264.7 cells. The expression of iNOS and COX-2 was analyzed using ImageJ and β-actin was analyzed. All data are expressed as mean ± SD ***P<0.001 compared to the control group and ###P<0.001 compared to the LPS group. Figure 4 shows the effect of fig fruit extract on LPS-stimulated activation of IκBα phosphorylation in Raw 264.7 cells. p-IκBα expression was analyzed using ImageJ and compared to β-actin. All data are expressed as mean ± SD ***P<0.001 compared to the control group and ###P<0.001 compared to the LPS group. Figure 5 shows the effect of fig fruit extract on p-JAK1 and p-STAT3 expression in Raw 264.7 cells. The expression of p-JAK1 (A) and p-STAT3 (B) was analyzed using ImageJ and compared with β-actin. All data are expressed as mean ± SD ***P<0.001 compared to the control group and ###P<0.001 compared to the LPS group. Figure 6 shows the effect of fig fruit extract on β-hexozaminidase release in DNP-IgE-stimated RBL-2H3 cells. Data are mean ± SD. ***P<0.001 compared to control, ###P<0.001 compared to DNP-IgE. Figure 7 shows the results of observing the dorsal skin phenotype of mice with IMQ-induced psoriasis-like skin lesions. Mice treated with daily topical application of Vaseline on shaved dorsal skin were used as controls. On the third day after IMQ treatment, the dorsal skin treated with daily IMQ (62.5 mg) shows psoriasis-like inflammation, erythematous lesions, and silvery-white keratin. IMQ: Imiquimod, DEX: Dexamethasone, FH: High concentration of fig extract, FM: Medium concentration of fig extract, FL: Low concentration of fig extract. Figure 8 shows PASI scores indicating skin erythema and scales on a 0-3 point scale for control and treated mice. Figure 9 shows the histological examination after staining with hematoxylin and eosin (H&E). It shows the H&E-stained dorsal skin of control and IMQ-treated mice. The image was magnified 40 times. Figure 10 shows the effect of fig fruit extract on the ratio of spleen weight to body weight. (